Venlafaxine updated on 07-01-2025

Persistent pulmonary hypertension

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S13135
R50112		 Marks (Controls exposed to Bupropion), 2021 Pulmonary Hypertension during pregnancy (anytime or not specified) retrospective cohort exposed to other treatment, sick Adjustment: No Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 3.08 [0.06;156.19] C 0/132   0/406 0 132
ref
S11794
R43395		 Bérard a, 2017 Persistent pulmonary hypertension of the newborn (PPHN) 2nd and/or 3rd trimester population based cohort propective unexposed (general population or NOS) Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 0.59 [0.06;5.62] -/419   258/141,097 - 419
ref
Total 2 studies 0.89 [0.13;6.37] 0 551
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Marks (Controls exposed to Bupropion), 2021Marks, 2021 1 3.08[0.06; 156.19]013225%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Bérard a, 2017Bérard a, 2017 0.59[0.06; 5.62]-41975%ROB confusion: seriousROB selection: moderateROB classification: criticalROB missing: moderateROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 0% 0.89[0.13; 6.37]-5510.210.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls exposed to Bupropion;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.89[0.13; 6.37]-5510%NAMarks (Controls exposed to Bupropion), 2021 Bérard a, 2017 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 0.59[0.06; 5.71]-419 -NABérard a, 2017 1 exposed to other treatment, sickexposed to other treatment, sick 3.08[0.06; 156.19]-132 -NAMarks (Controls exposed to Bupropion), 2021 1 Tags Adjustment   - No  - No 3.08[0.06; 156.19]-132 -NAMarks (Controls exposed to Bupropion), 2021 1   - Yes  - Yes 0.59[0.06; 5.71]-419 -NABérard a, 2017 1 Monotherapy   - substance alone among all Antidep ( ...  - substance alone among all Antidep (SSRI, SNRI, ...) 0.89[0.13; 6.37]-5510%NAMarks (Controls exposed to Bupropion), 2021 Bérard a, 2017 2 All studiesAll studies 0.89[0.13; 6.37]-5510%NAMarks (Controls exposed to Bupropion), 2021 Bérard a, 2017 20.210.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 0.59[0.06; 5.71]249419 -NABérard a, 2017 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 3.08[0.06; 156.19]-132 -NAMarks (Controls exposed to Bupropion), 2021 10.510.01.0